27th Jan 2015 07:00
27 January 2015
Silence Therapeutics plc
Grant of share options
Silence Therapeutics plc, AIM: SLN ('Silence' or 'the Company'), a leader in the development and delivery of RNA therapeutics for the treatment of serious diseases, has awarded options over 153,000 ordinary shares to its recently appointed Head of Research and Development, Dr Lars Karlsson, in accordance with the terms of the Company's share option plan.
The options will vest after three years and have an exercise price of 205p, being the closing price on 7 January 2015, the day before Dr Karlsson joined the Company. They are also subject to a 400p price hurdle.
Enquiries:
Silence Therapeutics plc | +44 (0)20 3700 9711 |
Timothy Freeborn, Finance Director | |
Rozi Morris, Communications Manager | |
Canaccord Genuity Limited | +44 (0)20 7523 8350 |
Dr Julian Feneley/Cara Griffiths/Henry Fitzgerald-O'Connor |
About Silence Therapeutics (www.silence-therapeutics.com)
Silence Therapeutics is a leading RNA therapeutics company. It has developed proprietary modifications to improve the robustness of RNA sequences together with advanced liposomal chemistries to enhance the delivery of its therapeutics. Its technology can selectively silence or replace the expression of any gene in the genome, modulating expression up as well as down in a variety of organs and cell types, in vivo. This allows the development of therapeutics for diseases with high unmet clinical need.
Related Shares:
SLN.L